Re: Clinical Outcomes in Octogenarians Treated with Docetaxel as First-Line Chemotherapy for Castration-Resistant Prostate Cancer

被引：0
|
作者：
Griebling, Tomas L.
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 197卷 / 01期
关键词：
D O I：
10.1016/j.juro.2016.10.035
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
  • [41] Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone
    Nieblas-Toscano, D.
    Arenas-Bonilla, A. J.
    Flores-Martin, J. F.
    Gutierrez-Tejero, F.
    Velarde-Munoz, C.
    Ramos-Alaminos, C., I
    Salas-Moreno, M. C.
    Galisteo-Moya, R.
    Moreno-Jimenez, J.
    ACTAS UROLOGICAS ESPANOLAS, 2020, 44 (03): : 164 - 171
  • [42] Chemotherapy for castration-resistant prostate cancer
    Berthold, D.
    ONKOLOGIE, 2011, 34 : 12 - 12
  • [43] Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer
    Christoph W. M. Reuter
    Michael A. Morgan
    Philipp Ivanyi
    Martin Fenner
    Arnold Ganser
    Viktor Grünwald
    World Journal of Urology, 2010, 28 : 391 - 398
  • [44] Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer
    Reuter, Christoph W. M.
    Morgan, Michael A.
    Ivanyi, Philipp
    Fenner, Martin
    Ganser, Arnold
    Gruenwald, Viktor
    WORLD JOURNAL OF UROLOGY, 2010, 28 (03) : 391 - 398
  • [45] A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC).
    Emmenegger, U.
    Berry, S. R.
    Booth, C. M.
    Sridhar, S. S.
    Winquist, E.
    Bandali, N.
    Chow, A.
    Kerbel, R.
    Ko, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC)
    Emmenegger, U.
    Berry, S. R.
    Booth, C.
    Sridhar, S. S.
    Winquist, E.
    Bandali, N.
    Chow, A.
    Kerbel, R. S.
    Ko, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [47] A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC)
    Emmenegger, U.
    Sridhar, S. S.
    Booth, C. M.
    Kerbel, R.
    Berry, S. R.
    Ko, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [48] Editorial Comment to Predictive factors of survival outcomes in first-line therapy for metastatic castration-resistant prostate cancer
    Yuasa, Takeshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (01) : 33 - 33
  • [49] Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel
    Ya-nan Man
    Yan-fang Chen
    International Urology and Nephrology, 2019, 51 : 2189 - 2199
  • [50] Systemic immune-inflammation index, serum albumin, and fibrinogen impact prognosis in castration-resistant prostate cancer patients treated with first-line docetaxel
    Man, Ya-nan
    Chen, Yan-fang
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2019, 51 (12) : 2189 - 2199
12345